These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 12674170

  • 1. Oral hypoglycaemic agent failure.
    Banerjee S, Sinharoy K, Singh AK.
    J Indian Med Assoc; 2002 Jul; 100(7):452-6. PubMed ID: 12674170
    [Abstract] [Full Text] [Related]

  • 2. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC, Tsang LW, Sorensen JP, Cockram CS.
    Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
    [Abstract] [Full Text] [Related]

  • 3. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
    Lin S, Chen M, Chen W, Lin K, Mu P, Zhu B, Xu W, Wang M, Weng J, Zeng L.
    J Diabetes Res; 2018 Mar; 2018():2791584. PubMed ID: 30420969
    [Abstract] [Full Text] [Related]

  • 4. Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.
    Joya-Galeana J, Fernandez M, Cervera A, Reyna S, Ghosh S, Triplitt C, Musi N, DeFronzo RA, Cersosimo E.
    Diabetes Metab Res Rev; 2011 May; 27(4):373-82. PubMed ID: 21309063
    [Abstract] [Full Text] [Related]

  • 5. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes.
    Katakami N, Yamasaki Y, Hayaishi-Okano R, Ohtoshi K, Kaneto H, Matsuhisa M, Kosugi K, Hori M.
    Diabetologia; 2004 Nov; 47(11):1906-13. PubMed ID: 15565373
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Correlates of treatment patterns among youth with type 2 diabetes.
    Badaru A, Klingensmith GJ, Dabelea D, Mayer-Davis EJ, Dolan L, Lawrence JM, Marcovina S, Beavers D, Rodriguez BL, Imperatore G, Pihoker C.
    Diabetes Care; 2014 Nov; 37(1):64-72. PubMed ID: 24026554
    [Abstract] [Full Text] [Related]

  • 9. Monitoring of metabolic control in patients with non-insulin-dependent diabetes mellitus on oral hypoglycaemic agents: value of evening blood glucose determination.
    Guillausseau PJ.
    Diabet Med; 1997 Sep; 14(9):798-802. PubMed ID: 9300232
    [Abstract] [Full Text] [Related]

  • 10. Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure.
    Altuntas Y, Ozen B, Ozturk B, Sengul A, Ucak S, Ersoy O, Karul S.
    Diabetes Obes Metab; 2003 Nov; 5(6):371-8. PubMed ID: 14617222
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
    Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, Hanefeld M.
    Diabetologia; 2005 Jun; 48(6):1093-104. PubMed ID: 15889234
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
    Filozof C, Gautier JF.
    Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
    [Abstract] [Full Text] [Related]

  • 16. Medium-term hypoglycaemic effects of two different oral formulations of gliclazide.
    Galeone F, Fiore G, Mannucci E.
    Diabet Med; 1999 Jul; 16(7):618-9. PubMed ID: 10445842
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Metformin added to insulin therapy in poorly controlled type 2 diabetes.
    Hirsch IB.
    Diabetes Care; 1999 May; 22(5):854. PubMed ID: 10332695
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.